Early Referral to a Nephrologist Improved Patient Survival: Prospective Cohort Study for End-Stage Renal Disease in Korea

Do Hyoung Kim1,9, Myounghee Kim2,9, Ho Kim3,9, Yong-Lim Kim4,9, Shin-Wook Kang5,9, Chul Woo Yang6,9, Nam-Ho Kim7,9, Yon Su Kim1,9, Jung Pyo Lee8,9*

1 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, 2 Department of Dental Hygiene, College of Health Science, Eulji University, Seongnam, Korea, 3 Department of Epidemiology and Biostatistics, School of Public Health, Seoul National University, Seoul, Korea, 4 Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, 5 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 6 Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea, 7 Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea, 8 Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea, 9 Clinical Research Center for End Stage Renal Disease in Korea, Daegu, Korea

Abstract

The timing of referral to a nephrologist may influence the outcome of chronic kidney disease patients, but its impact has not been evaluated thoroughly. The results of a recent study showing an association between early referral and patient survival are still being debated. A total of 1028 patients newly diagnosed as end-stage renal disease (ESRD) from July 2008 to October 2011 were enrolled. Early referral (ER) was defined as patients meeting with a nephrologist more than a year before dialysis and dialysis education were provided, and all others were considered late referral (LR). The relationship of referral pattern with mortality in ESRD patients was explored using a Cox proportional hazards regression models. Time from referral to dialysis was significantly longer in 599 ER patients than in 429 LR patients (62.3 ± 58.9 versus 2.9 ± 3.4 months, P < 0.001). Emergency HD using a temporary vascular catheter was required in 485 (47.2%) out of all patients and in 262 (43.7%) of ER compared with 223 (52.0%) of LR (P = 0.009). After 2 years of follow-up, the survival rate in ER was better than that in LR (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.27–4.45, P = 0.007). In patients with diabetes nephropathy, patient survival was also significantly higher in ER than in LR (HR 4.74, 95% CI 1.73–13.00, P = 0.002). With increasing age, HR also increased. Timely referral to a nephrologist in the predialytic stage is associated with reduced mortality.

Introduction

Patients with end-stage renal disease (ESRD) have an exceedingly high morbidity and mortality compared to the general population [1]. The number of ESRD patients is growing at a much faster rate than the total population. The increasing prevalence of ESRD has led to its recognition as a significant clinical and public health problem, in terms of its use of medical resources and public health expenditure. According to data from the National Health Insurance Corporation, chronic kidney disease (CKD) ranked first in public health expenditure [2]. Also, it was the single most expensive disease.

Over the past several years, interest has evolved in evaluating the timing of nephrology referral in the predialytic stage of CKD. The potential benefits of timely nephrology referral include identification of reversible causes of CKD, provision of treatments that may slow the progression of CKD, management of the metabolic complications of advanced CKD, coordination of education regarding ESRD treatment options, and optimal preparation for the chosen dialysis modality or kidney transplantation [3]. Therefore, delayed nephrology care could be associated with several unfavorable outcomes, including reduced access to peritoneal dialysis (PD) [4,5] and kidney transplantation [6,7], higher rates of dialysis initiation through a temporary venous catheter, and an higher mortality rate after starting maintenance dialysis, especially during the first few months [8–10].

To date, most referral studies have had a retrospective design [4,5,11–13] and there have been few prospective multi-center studies examining referral practices [14,15]. The results of a recent study showing an association between early referral and patient survival are still being debated [16]. Additionally, late referral was defined as the first encounter with a nephrologist occurring within 1 to 3 months of the commencement of dialysis in most studies. This duration was too short to ensure effective education of the patients by the nephrologist [17]. Therefore, a large prospective study is required to investigate the relationship between early referral to a nephrologist and patient survival.
Table 1. Patient characteristics by referral pattern.

|                          | Total ESRD | Early referral (N=1028) | Late referral (N=511) | P Value | DM ESRD | Early referral (N=511) | Late referral (N=209) | P Value |
|--------------------------|------------|--------------------------|-----------------------|---------|---------|--------------------------|-----------------------|---------|
| Age at the time of dialysis (year) | 57.0±13.9 | 57.4±13.5 | 56.5±14.4 | 0.329 | 59.1±11.5 | 59.9±11.4 | 57.8±11.5 | 0.044 |
| Gender (male, %) | 59.6 | 58.3 | 61.5 | 0.303 | 63.0 | 60.6 | 66.5 | 0.174 |
| Length of follow-up (mo) | 10.2±6.9 | 10.7±7.1 | 9.4±6.6 | 0.003 | 10.1±6.8 | 10.8±7.3 | 9.1±5.9 | 0.004 |
| Drop out (N, %) | 95 (9.2) | 49 (8.2) | 46 (10.7) | 0.190 | 46 (9.0) | 24 (7.9) | 22 (10.5) | 0.347 |
| Findings at the time of referral to nephrologist | | | | | | | | |
| Underlying kidney disease (%) | 0.181 | | | | | | | |
| Diabetes mellitus | 49.7 | 50.4 | 48.7 | | | | | |
| Hypertension | 17.5 | 15.5 | 20.3 | | | | | |
| Glomerulonephritis | 15.3 | 18.0 | 11.4 | | | | | |
| Polycystic kidney disease | 2.0 | 2.8 | 0.9 | | | | | |
| Others | 7.8 | 8.0 | 7.5 | | | | | |
| Unknown | 7.7 | 5.2 | 11.2 | | | | | |
| Systolic BP (mmHg) | 147.1±27.6 | 143.3±26.8 | 151.0±28.0 | <0.001 | 146.0±26.2 | 143.8±26.2 | 148.7±26.0 | 0.086 |
| Diastolic BP (mmHg) | 84.7±16.5 | 83.4±16.0 | 86.1±16.9 | 0.032 | 81.3±14.8 | 80.5±15.1 | 82.2±14.5 | 0.311 |
| Serum creatinine (mg/dL) | 4.8±4.1 | 2.6±1.5 | 7.2±4.6 | <0.001 | 4.1±3.0 | 2.6±1.4 | 6.0±3.4 | <0.001 |
| eGFR (mL/min/1.73m²) | 24.5±33.9 | 36.1±42.7 | 11.4±8.0 | <0.001 | 24.5±21.3 | 34.2±24.0 | 12.8±8.2 | <0.001 |
| Hemoglobin (g/dL) | 100±5.0 | 112±6.4 | 88±1.8 | <0.001 | 97±1.9 | 105±1.8 | 89±1.7 | <0.001 |
| Number of visits to nephrologist from referral to dialysis (%) | | | | <0.001 | | | | <0.001 |
| None | 8.6 | 0 | 20.5 | 0.61 | 0 | 14.8 |
| 1 time | 7.4 | 1.8 | 15.2 | 0.67 | 2.3 | 12.9 |
| 2 times or more | 84.0 | 98.2 | 64.3 | 0.87 | 97.7 | 72.2 |
| Time from referral to dialysis (month) | 37.7±53.8 | 62.3±58.9 | 29±3.4 | <0.001 | 29.1±37.0 | 46.8±39.1 | 3.3±3.5 | <0.001 |
| Findings at the time of dialysis | | | | | | | | |
| Modified Charlson co-morbidity index | 5.1±2.5 | 5.2±2.5 | 5.0±2.5 | 0.218 | 6.1±2.2 | 6.2±2.3 | 6.0±2.1 | 0.189 |
| Davies co-morbidity index | 1.0±0.9 | 1.0±0.9 | 1.0±1.0 | 0.919 | 1.5±0.8 | 1.5±0.8 | 1.6±0.8 | 0.656 |
| Serum creatinine (mg/dL) | 8.4±3.9 | 8.3±3.6 | 8.5±4.2 | 0.147 | 7.8±3.1 | 7.8±3.1 | 7.7±3.2 | 0.642 |
| eGFR (mL/min/1.73m²) | 7.6±3.4 | 7.5±3.2 | 7.7±3.7 | 0.288 | 81.3±3.4 | 79.3±3.2 | 84.3±3.6 | 0.115 |
| Hemoglobin (g/dL) | 9.0±3.5 | 8.9±1.6 | 8.8±1.7 | 0.468 | 9.1±3.8 | 8.9±1.5 | 8.9±1.6 | 0.854 |
| Transferrin saturation (%) | 33.3±51.8 | 33.0±46.2 | 33.8±58.6 | 0.825 | 32.4±62.3 | 30.9±44.6 | 34.5±81.2 | 0.553 |
| Hemoglobin A1c (%) | 6.9±2.5 | 6.9±1.7 | 6.6±1.3 | 0.039 | | | | |
| Uric acid (mg/dL) | 8.2±5.1 | 8.0±2.5 | 8.2±2.6 | 0.228 | 8.2±5.5 | 8.0±2.4 | 7.9±2.3 | 0.850 |
|                  | Total ESRD | Early referral (N=599) | Late referral (N=429) | P Value  | DM ESRD | Early referral (N=302) | Late referral (N=209) | P Value |
|------------------|------------|------------------------|-----------------------|----------|---------|------------------------|-----------------------|----------|
| Calcium (mg/dL)  | 7.9 ± 3.9  | 7.8 ± 1.0              | 7.7 ± 1.1             | 0.331    | 8.0 ± 2.2 | 7.8 ± 0.9              | 7.7 ± 0.9             | 0.148    |
| Phosphate (mg/dL)| 5.5 ± 3.0  | 5.3 ± 1.8              | 5.6 ± 2.0             | 0.042    | 5.5 ± 2.8 | 5.3 ± 1.7              | 5.5 ± 1.8             | 0.437    |
| iPTH (pg/mL)     | 256.0 ± 239.9 | 267.2 ± 238.0        | 240.0 ± 210.9         | 0.105    | 219.0 ± 189.5 | 218.1 ± 174.8        | 220.4 ± 210.4        | 0.905    |
| Systolic BP (mmHg)| 140.3 ± 23.7 | 138.2 ± 23.8         | 143.2 ± 23.3          | 0.001    | 141.8 ± 24.5 | 139.8 ± 24.5        | 144.9 ± 24.1         | 0.023    |
| Diastolic BP (mmHg)| 78.4 ± 14.1  | 77.3 ± 13.2           | 80.1 ± 15.0           | 0.002    | 76.7 ± 13.1  | 75.4 ± 12.4           | 78.5 ± 13.4          | 0.008    |
| Calcium (mg/dL)  | 23.3 ± 6.3  | 23.1 ± 3.3             | 23.6 ± 8.9            | 0.211    | 23.5 ± 3.4  | 23.6 ± 3.3            | 23.4 ± 3.6           | 0.625    |
| Total cholesterol (mg/dL) | 192.2 ± 50.7 | 156.2 ± 48.5         | 163.4 ± 53.2          | 0.300    | 157.7 ± 55.7 | 153.5 ± 51.1        | 163.9 ± 61.4         | 0.053    |
| BMI (kg/m²)      | 32.8 ± 6.3  | 32.7 ± 6.3             | 33.0 ± 6.3            | 0.001    | 32.5 ± 6.3  | 32.5 ± 6.3            | 33.0 ± 6.3           | 0.001    |
| Total cholesterol (mg/dL) | 186.3 ± 19.6 | 186.2 ± 19.6         | 186.4 ± 19.7          | 0.001    | 186.3 ± 19.6 | 186.4 ± 19.7        | 186.4 ± 19.7         | 0.001    |
| HDL cholesterol (mg/dL) | 93.6 ± 55.1  | 90.0 ± 53.7           | 98.5 ± 56.6           | 0.038    | 93.6 ± 55.1  | 90.1 ± 60.0          | 100.0 ± 67.8         | 0.117    |
| HDL cholesterol (mg/dL) | 39.7 ± 14.3   | 39.7 ± 14.6           | 39.8 ± 13.9           | 0.902    | 38.3 ± 13.2  | 37.6 ± 12.3          | 39.5 ± 14.3          | 0.149    |

aValues for continuous variables are means ± standard deviation; values for categorical variables expressed as proportion. BP, blood pressure; eGFR, estimated glomerular filtration rate; iPTH, intact parathyroid hormone; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

doi:10.1371/journal.pone.0055323.t001

Figure 1. Pattern of emergency dialysis using a temporary vascular catheter according to the timing of referral.

Study Design and Methods

Subjects and Methods

This study was a multi-center, prospective cohort study of patients with ESRD in Korea who were initiated on dialysis before ESRD treatment initiation. The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

Early Referral Improved Survival

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.

The purpose of this study was to explore the impact of early referral on survival in patients with ESRD in Korea.
Table 2. Univariate analysis of predictors associated with mortality.*

| Variable                                               | Total ESRD (N=1028) | DM ESRD (N=511) |   |
|--------------------------------------------------------|---------------------|-----------------|---|
|                                                        | HR                  | 95% CI          | P Value | HR           | 95% CI          | P Value |
| Age at the time of dialysis (per year increase)         | 1.07                | 1.04–1.09       | <0.001  | 1.08         | 1.05–1.12       | <0.001  |
| Gender (female)                                         | 0.95                | 0.58–1.57       | 0.851    | 1.23         | 0.65–2.35       | 0.523    |
| Underlying kidney disease                               |                     |                 |         |              |                 |         |
| Diabetes mellitus                                       | Ref                 |                 |         |              |                 |         |
| Hypertension                                            | 0.56                | 0.25–1.25       | 0.154    |              |                 |         |
| Glomerulonephritis                                      | 0.63                | 0.30–1.30       | 0.207    |              |                 |         |
| Polycystic kidney disease                               | 0.59                | 0.08–4.27       | 0.598    |              |                 |         |
| Others                                                  | 0.70                | 0.25–1.96       | 0.497    |              |                 |         |
| Unknown                                                 | 1.17                | 0.49–2.77       | 0.727    |              |                 |         |
| Number of visits to nephrologist from referral to dialysis | 0.95                | 0.28–2.27       | 0.668    | 0.71         | 0.14–3.52       | 0.675    |
| None                                                    | 0.79                | 0.28–2.27       | 0.668    | 0.71         | 0.14–3.52       | 0.675    |
| 1 time                                                  | 0.52                | 0.23–1.15       | 0.104    | 0.43         | 0.13–1.41       | 0.163    |
| 2 times or more                                         | 2.16                | 1.32–3.53       | 0.003    | 2.42         | 1.26–4.64       | 0.008    |
| Late referral (ref = Early referral)                    |                      |                 |         |              |                 |         |
| Emergency HD (ref = no)                                 | 2.16                | 1.32–3.53       | 0.003    | 2.42         | 1.26–4.64       | 0.008    |
| Hospitalization (ref = no)                              | 1.63                | 1.00–2.67       | 0.001    | 1.08         | 0.57–2.04       | 0.812    |
| Findings at the time of dialysis                         | 2.75                | 1.66–4.56       | 0.001    | 2.07         | 1.05–4.07       | 0.035    |
| Modified Charlson co-morbidity index                     | 1.33                | 1.22–1.46       | <0.001   | 1.26         | 1.10–1.43       | 0.001    |
| Davies co-morbidity index                               | 1.65                | 1.32–2.06       | <0.001   | 1.44         | 1.00–2.07       | 0.052    |
| eGFR (mL/min/1.73m²)                                     | 1.13                | 1.06–1.20       | <0.001   | 1.08         | 0.99–1.17       | 0.090    |
| Hemoglobin (g/dL)                                        | 1.02                | 0.88–1.18       | 0.775    | 0.93         | 0.75–1.15       | 0.505    |
| Transferrin saturation (%)                              | 1.00                | 0.99–1.01       | 0.692    | 1.00         | 0.99–1.01       | 0.865    |
| Hemoglobin A1c (%)                                       | 0.99                | 0.77–1.27       | 0.922    |              |                 |         |
| Uric acid (mg/dL)                                        | 0.95                | 0.86–1.06       | 0.365    | 1.01         | 0.88–1.15       | 0.891    |
| Calcium (mg/dL)                                          | 1.11                | 0.88–1.40       | 0.392    | 0.91         | 0.65–1.27       | 0.571    |
| Phosphatate (mg/dL)                                     | 0.82                | 0.71–0.95       | 0.007    | 0.82         | 0.67–1.01       | 0.060    |
| iPTH (pg/mL)                                             | 1.00                | 0.99–1.00       | 0.020    | 1.00         | 0.99–1.00       | 0.883    |
| Systolic BP (mmHg)                                      | 1.00                | 0.99–1.01       | 0.958    | 1.00         | 0.98–1.01       | 0.620    |
| Diastolic BP (mmHg)                                     | 0.98                | 0.97–1.00       | 0.082    | 1.00         | 0.97–1.02       | 0.915    |
| BMI (kg/m²)                                              | 0.92                | 0.85–1.00       | 0.046    | 0.84         | 0.75–0.95       | 0.004    |
| Total cholesterol (mg/dL)                               | 1.00                | 0.99–1.00       | 0.192    | 1.00         | 0.99–1.00       | 0.386    |
| Triglycerides (mg/dL)                                   | 1.00                | 0.99–1.00       | 0.568    | 1.00         | 0.99–1.00       | 0.456    |
| LDL cholesterol (mg/dL)                                 | 0.99                | 0.99–1.00       | 0.146    | 0.99         | 0.98–1.00       | 0.231    |
| HDL cholesterol (mg/dL)                                 | 0.99                | 0.97–1.01       | 0.438    | 0.99         | 0.97–1.02       | 0.684    |

*HR, hazard ratio; CI, confidence interval; BP, blood pressure; HD, hemodialysis; eGFR, estimated glomerular filtration rate; iPTH, intact parathyroid hormone; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

doi:10.1371/journal.pone.0055323.t002

written consent to participate in this study. All traceable identifiers were removed before analysis to protect patient confidentiality. The study was approved by the institutional review board at each center [The Catholic University of Korea, Bucheon St. Mary’s Hospital; The Catholic University of Korea, Incheon St. Mary’s Hospital; The Catholic University of Korea, Seoul St. Mary’s Hospital; The Catholic University of Korea, St. Mary’s Hospital; The Catholic University of Korea, St. Vincent’s Hospital; The Catholic University of Korea, Uijeongbu St. Mary’s Hospital; Cheju Halla General Hospital; Chonbuk National University Hospital; Chung-Ang University Medical Center; Chungbuk National University Hospital; Chungnam National University Hospital; Dong-A University Medical Center; Ewha Womans University Medical Center; Fatima Hospital, Daegu; Gachon University Gil Medical Center; Inje University Pusan Paik Hospital; Kyungpook National University Hospital; Kwandong University College of Medicine, Myongji Hospital; National Health Insurance Corporation Ilsan Hospital; National Medical Center; Pusan National University Hospital; Samsung Medical Center, Seoul; Seoul Metropolitan Government, Seoul National University Hospital; Seoul National University, Bundang Hospital; Yeungnam University Medical Center; Yonsei University, Severance Hospital; Yonsei University, Gangnam Severance Hospital; Ulsan University Hospital; Wonju Christian Hospital (in alphabetical order)]. All clinical investiga-
tions were conducted in accordance with the guidelines of the 2008 Declaration of Helsinki.

Outcomes
The primary outcome of interest was all-cause mortality after initiation of dialysis in the LR versus ER patients. The secondary outcomes consisted of various clinical and laboratory parameters in the LR versus ER group: emergency hemodialysis (HD), cardiovascular death, cause of death, hospitalization.

Data Sources
CRC ESRD served as the primary source of data for these analyses. Clinical and laboratory data were collected by web-based medical and patient questionnaires [20]. Each center collected the information of several outcomes including cause of death with the clinical and laboratory data in this study. Then, they reported to CRC-ESRD web-based registry about the outcomes. Research coordinators from central center carried out a regular sample survey on enrolled patients to confirm the medical records twice a year. They had checked all the

| Table 3. Multivariate Cox proportional hazard models of independent factors of survival.a |
|---------------------------------|---------|---------|---------|
|                                 | Model 1 | Model 2 | Model 3 |
| Type of referral                |         |         |         |
| Early referral                  | Ref     | Ref     | Ref     |
| Late referral                   | 2.16 (1.32–3.53) | 0.002   | 2.28 (1.39–3.74) | 0.001 |
| Age (years)                     | 3.73 (2.43–5.73) | <0.001  | 1.06 (1.03–1.09) | <0.001 |
| Gender (female)                 | 0.87 (0.53–1.44) | 0.599   | 1.11 (0.56–2.21) | 0.760 |
| BMI                             |         |         |         |
| Calcium                         | 1.00 (0.93–1.08) | 0.964   | 1.09 (0.93–1.28) | 0.268 |
| Modified Charlson comorbidity index | 1.10 (0.94–1.33) | 0.504   |           |
| HDL cholesterol                 | 1.00 (0.97–1.03) | 0.897   |           |
| Triglycerides                   | 1.00 (1.00–1.01) | 0.822   |           |
| Total cholesterol               | 1.00 (1.00–1.01) | 0.326   |           |
| Hemoglobin                      | 0.90 (0.73–1.10) | 0.302   |           |
| eGFR                            | 1.03 (0.94–1.13) | 0.504   |           |
| iPTH                            | 1.00 (1.00–1.00) | 0.163   |           |
| Uric acid                       | 1.02 (0.91–1.14) | 0.794   |           |
| SBP at the time of dialysis     | 1.00 (0.98–1.01) | 0.744   |           |

DM ESRD patients (N=511) Model 1 Model 2 Model 3
| Type of referral                |         |         |         |
| Early referral                  | Ref     | Ref     | Ref     |
| Late referral                   | 2.42 (1.26–4.64) | 0.008   | 2.88 (1.49–5.59) | 0.002 |
| Age (years)                     | 3.71 (2.17–6.34) | <0.001  | 1.08 (1.03–1.13) | 0.002 |
| Gender (female)                 | 1.30 (0.67–2.52) | 0.437   | 1.90 (0.67–5.38) | 0.230 |
| BMI                             | 0.83 (0.70–0.99) | 0.042   |           |
| Calcium                         | 1.00 (0.81–1.22) | 0.989   |           |
| Modified Charlson comorbidity index | 1.10 (0.87–1.39) | 0.440   |           |
| HDL cholesterol                 | 1.00 (0.95–1.04) | 0.843   |           |
| Triglycerides                   | 1.00 (0.99–1.01) | 0.640   |           |
| Total cholesterol               | 1.01 (0.99–1.02) | 0.331   |           |
| Hemoglobin                      | 0.67 (0.50–0.91) | 0.010   |           |
| eGFR                            | 1.03 (0.89–1.18) | 0.713   |           |
| iPTH                            | 1.00 (1.00–1.00) | 0.162   |           |
| Uric acid                       | 1.03 (0.87–1.22) | 0.727   |           |
| SBP at the time of dialysis     | 0.99 (0.98–1.01) | 0.341   |           |

*HR, hazard ratio; CI, confidence interval; BMI, body mass index; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; iPTH, intact parathyroid hormone; SBP, systolic blood pressure.

doi:10.1371/journal.pone.0055323.t003
medical records of patients who died in hospital registered in CRC-ESRD to confirm the cause-specific death and the mortality date. In the case of patient death in other hospitals, information of cause-specific death was extracted from the Korean National Statistical Office data as of December 31, 2010.

A medical questionnaire was completed by data coordinators, who were trained in each center to collect patient data by a combination of chart reviews and informal interviews using a standardized form. The questionnaires included data on demographics, previous medical history, laboratory results, dialysis modality and prescription, presence and type of permanent access used for the first dialysis, and medications including erythropoietin use. eGFR, modified Charlson co-morbidity index (CCI), and Davies co-morbidity index (DCI) at the initiation of dialysis were recorded for each patient.

The modified CCI and DCI values were calculated using the method described in a previous study [21–23]. The modified CCI includes age (weight 1 for every 10 years starting from 50 years of age) and contains 19 categories of comorbidities including congestive heart failure (weight 1), myocardial infarction (weight 1), chronic pulmonary disease (weight 1), cerebrovascular disease (weight 1), hemiplegia or paraplegia (weight 2), dementia (weight 1), diabetes (weight 1), diabetes with complications (weight 2), leukemia (weight 2), lymphoma (weight 2), malignancy (weight 2), metastatic solid tumor (weight 6), mild liver disease (weight 1), moderate or severe liver disease (weight 3), peptic ulcer disease (weight 1), peripheral vascular disease (weight 1), rheumatologic disease (weight 1), renal disease (weight 2) and acquired immune deficiency syndrome (weight 6) [21,22]. The DCI includes malignancy (1 point), ischemic heart disease (1 point), peripheral vascular disease (1 point), left ventricular dysfunction (1 point), diabetes mellitus (1 point), systemic collagen vascular disease (1 point), and other significant pathology (1 point). These data were obtained from a systematic review of all available records [23].

Patients who responded to the questionnaire were asked when they first received medical attention from a kidney specialist before starting dialysis. In a similar fashion, respondents to the questionnaire were asked about the number of visits they had with a nephrologist during the year and about education concerning dialysis and diet before the start of ESRD.

Statistical Analysis

Univariate analyses of the differences in the clinical and laboratory variables between ER and LR were performed using the \( t \) test for continuous variables and the chi-square or Fisher exact test for discrete variables. The multivariate Cox proportional hazards regression models were used to explore the relationships of each of the independent factors with mortality risk in ESRD patients. A stepwise selection process was used to develop the multivariate Cox proportional hazards regression model. Model 1 was built to explore the relationship of timing of referral with mortality risk without the use of any explanatory variables. Model 2 was only controlled for age and gender. Model 3 was adjusted for body mass index (BMI), modified CCI, serum calcium, high-density lipoprotein cholesterol, triglycerides, total cholesterol, hemoglobin, intact parathyroid hormone, uric acid, and eGFR. The effects of the multivariate Cox proportional hazards regression models are shown as hazard ratio (HR) and 95% confidence index (CI). The Kaplan-Meier method was used to compare survival curves, and differences were assessed by means of the log rank test. The statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and R 2.14.1. Significant differences were defined as \( P \) less than 0.05.

Results

Patient Characteristics by Referral Pattern

Of 1028 patients enrolled in the CRC ESRD, 599 were referred early and 429 were referred late. Patients’ clinical and laboratory characteristics are listed in Table 1. Time from referral to dialysis was significantly longer in the ER group compared to the LR group (62.3±58.9 months versus 2.9±3.4 months, \( P<0.001)\). The most common etiology of kidney failure was diabetic nephropathy in both groups. At the time of referral to a nephrologist, blood pressure (BP) was lower, renal function was better, and hemoglobin level was higher in the ER group compared to the LR group.
However, at the time of dialysis, most findings including co-morbidity index were similar in both groups, except for BP, serum phosphate, total cholesterol, and low-density lipoprotein (LDL) cholesterol. Hemoglobin level or iron status was the same for the two groups. BP was well controlled in the ER group. Serum phosphate, total cholesterol, and LDL cholesterol levels in the ER group were significantly lower than for the LR group.

There were no significant differences in clinical and laboratory characteristics at the time of dialysis between the ER group and the LR group with diabetes nephropathy as a cause of ESRD (DM ESRD), except in terms of BP and hemoglobin A1c.

Emergency HD using a temporary vascular catheter was required in 262 of 599 ER patients compared to 223 of 429 LR patients. The rate of emergency HD in ER patients was significantly lower than in LR patients (Figure 1, 43.7% versus 52.0%, P = 0.009).

### Table 4. Cause of death in patients.

| Cause of death                                      | Total |  |  |  |  |  |
|-----------------------------------------------------|-------|--|--|--|--|--|
|                                                     | Early referral (M) | Late referral (M) | Sum (M) | Early referral (M) | Late referral (M) | Sum (M) |
| Cardiovascular disease                               | 2     | 2 | 0 | 0 | 0 | 0 |
| Myocardial infarction                               | 0     | 2 | 2 | 0 | 2 | 2 |
| Cardiomyopathy                                      | 0     | 1 | 1 | 0 | 0 | 0 |
| Cardiac arrest, cause unknown                        | 4     | 6 | 10 | 2 | 3 | 5 |
| Pulmonary edema                                     | 0     | 2 | 2 | 0 | 1 | 1 |
| Pulmonary embolus                                   | 0     | 1 | 1 | 0 | 0 | 0 |
| Cerebrovascular accident including intracranial hemorrhage | 1     | 0 | 1 | 1 | 0 | 1 |
| Hemorrhage from ruptured vascular aneurysm          | 1     | 1 | 2 | 0 | 0 | 0 |
| Other hemorrhage                                    | 0     | 1 | 1 | 0 | 1 | 1 |
| Mesenteric infarction/ischemic bowel                 | 0     | 1 | 1 | 0 | 1 | 1 |
| Infection                                           | 0     | 1 | 1 | 0 | 1 | 1 |
| Peritoneal access infectious complication, bacterial | 0     | 1 | 1 | 0 | 1 | 1 |
| Peritoneal access infectious complication, fungal    | 0     | 1 | 1 | 0 | 1 | 1 |
| Peritonitis (complication of peritoneal dialysis)    | 0     | 1 | 1 | 0 | 0 | 0 |
| Septicemia, other                                   | 4     | 2 | 6 | 1 | 2 | 3 |
| Cardiac infection (endocarditis)                    | 0     | 1 | 1 | 0 | 1 | 1 |
| Pulmonary infection (pneumonia, influenza)          | 4     | 6 | 10 | 2 | 4 | 6 |
| Liver disease                                       | 0     | 1 | 1 | 0 | 0 | 0 |
| Liver failure, cause unknown or other                | 0     | 1 | 1 | 0 | 0 | 0 |
| Gastro-intestinal disease                           | 1     | 0 | 1 | 0 | 0 | 0 |
| Perforation of bowel                                | 2     | 0 | 2 | 0 | 1 | 1 |
| Other                                                                                               |
| Cachexia/failure to thrive                           | 2     | 0 | 2 | 0 | 1 | 1 |
| Malignant disease, patient on immunosuppressive therapy | 0     | 3 | 3 | 0 | 1 | 1 |
| Malignant disease                                   | 0     | 1 | 1 | 0 | 1 | 1 |
| Hyperkalemia                                        | 0     | 1 | 1 | 0 | 1 | 1 |
| Suicide                                             | 0     | 1 | 1 | 0 | 1 | 1 |
| Other cause of death                                 | 2     | 2 | 4 | 2 | 1 | 3 |
| Unknown                                             | 5     | 6 | 11 | 3 | 4 | 7 |
| Sum                                                 | 26    | 40 | 66 | 14 | 23 | 37 |

doi:10.1371/journal.pone.0055323.t004

**Improved Survival in Early Referral Patients with End-stage Renal Disease**

In the univariate analysis, late referral was significantly associated with patient mortality (HR 2.16, 95% CI 1.32–3.53, P = 0.002). Age (HR 1.07, 95% CI 1.04–1.09, P < 0.001), hospitalization (HR 2.75, 95% CI 1.66–4.56, P < 0.001), modified CCI (HR 1.33, 95% CI 1.22–1.46, P < 0.001), DCI (HR 1.65, 95% CI 1.32–2.06, P < 0.001), and eGFR (HR 1.13, 95% CI 1.06–1.20, P < 0.001) were also significant risk factors associated with increased risk of death (Table 2). Variables that proved significant in the univariate analysis and referral pattern were included in the multivariate Cox proportional hazards model to determine factors associated with mortality. In the multivariate Cox analysis, late referral (HR 2.38, 95% CI 1.27–4.45, P = 0.007) and age (HR
The survival rate in ER patients was significantly higher than that in LR patients after adjusting for several risk factors of model 3 (Figure 2A, P = 0.005). The 1-year and 2-year survival rates in ER patients were 97.2% and 95.7%, respectively, compared to 93.9%, and 91.3% in LR patients.

Next, we performed a subgroup analysis in the DM ESRD patients. In DM ESRD patients, age (HR 1.08, 95% CI 1.05–1.12, P < 0.001), late referral (HR 2.42, 95% CI 1.26–4.64, P = 0.008), hospitalization (HR 2.07, 95% CI 1.05–4.07, P = 0.035), and modified CCI (HR 1.26, 95% CI 1.10–1.43, P = 0.001) were the univariate factors associated with increased risk of death. In the multivariate Cox analysis, late referral (HR 4.74, 95% CI 1.73–13.00, P = 0.002) and age (HR 1.08, 95% CI 1.03–1.13, P = 0.002) had an adverse association with survival (Table 3). The survival rate in ER patients was significantly higher than that in LR patients (Figure 2B, P = 0.003).

During follow-up, 66 patients (6%) died overall. Causes of death are listed in Table 4. Cardiovascular death represented the most common cause of death (32%), followed by infection (30%), unknown cause (17%), and neoplasm (8%). The remaining deaths (13%) were due to other causes (Table 4). In LR, cardiovascular death was the most common cause of death. However, infection was the most common cause of death in ER. In the Kaplan-Meier analysis, the cardiovascular death free survival rate was significantly worse in LR patients compared with ER patients in total (P = 0.004) and DM ESRD (P = 0.000). In the multivariate Cox analysis, LR (Table S1, HR 4.99, 95% CI 1.48–16.82, P = 0.009) was significant risk factors associated with cardiovascular death. Among patients with DM ESRD, LR was still significant factor associated with increased risk of cardiovascular death (Table S1, HR 26.71, 95% CI 1.49–478.99, P = 0.026).

Hospitalization-free survival rate and cardiovascular event-free survival rates were not different between ER and LR patients (data not shown).

Relationship between Mortality and Age at the Time of Referral

The relationship between age and mortality was evaluated. As the age of patients increased, the hazard ratio for death also increased (Figure 3A). In particular, in older patients the hazard ratios for ER and LR patients were quite different, with survival rates for ER patients increasing against LR patients. This trend was observed in DM ESRD patients (Figure 3B).

Discussion

The present nationwide multi-center prospective cohort study showed that early nephrology referral in the predialytic stage of CKD improves survival rate in ESRD. Late referral remains an important predictor of mortality even after adjusting for age, gender, co-morbidity, BMI, and biochemical variables.

Previous studies on the association of the timing of referral to a nephrologist with mortality have demonstrated conflicting results. Kazmi et al. studied 2,195 patients between 1996 and 1997 and found that, compared with ER patients, LR (<4 months) patients had a 44% higher risk of death at 1 year after initiation of dialysis, which remained significant after adjusting for the quintile of the propensity score [11]. Dogan et al. studied 101 patients between 1998 and 2002 and found that ER (>12 weeks) and/or early diagnosis of ESRD resulted in better biochemical variables, shorter length of first hospitalization, a higher percentage of elective construction of arteriovenous fistula, and the availability to start with an alternative dialysis modality [12]. In contrast, two studies have shown no difference in mortality between ER and LR patients. Schmidt et al. showed that there was no statistically significant difference in long-term survival when ER (>1 month) patients were compared with LR patients at 4 months among 238 patients [13]. Rouhiö et al. showed that the referral pattern (LR <4 months) was not associated with mortality rate among 270 patients [24].

Many previous studies incorporated an observational retrospective design, and the definition of the timing of ER was different in each study. In addition, some prospective studies were of small size and/or single-center design. Furthermore, the referral timing of 3 months or more in most previous studies was too short to assess and educate patients.

In a recent study, Di Napoli et al. reported that late referral patients had a lower frequency of hepatitis B virus vaccination, arteriovenous fistula and information about renal replacement therapy modalities, and they more often started chronic dialysis in an emergency [18]. They defined LR patients as those who had...
not been regularly referred to a nephrologist in the one year before chronic dialysis began. And, they considered a period of 12 months as adequate to describe the role of individual and health service characteristics in early access to renal services for ESRD care. In addition, de Jager DJ et al. classified referral (time between first pre-dialysis visit to a nephrologist and dialysis initiation) as: late (<3 months), early (3–12 months) or very early (≥12 months). They reported that early and late referrals were associated with increased mortality compared with very early referral [25]. Quaglia M et al. also mentioned that predialysis nephrology care had a much wider concept than providing the patient with a dialysis access and consequently demanded a longer time (ie, several years) to produce results, and that 3-month period before dialysis was inadequate to assess any impacts on hard end points [17].

This study is a prospective nationwide multi-center cohort study. ER was defined as a group undergoing follow-up for 12 months or longer prior to the initiation of dialysis. And, a 1-year period before dialysis was enough to control a BP, metabolic condition of patients, and provided the predialysis care for patients. Thus, this study design provides for a proper evaluation of the association between referral pattern and mortality in ESRD patients.

Our study showed that the mortality rate increased by 2.4 times during overall follow-up and this risk remained after adjusting for age, gender, and other covariates. Furthermore, we analyzed the cause of death in ESRD patients according to referral pattern. There were few researches studied about association between referral pattern and causes of death in dialysis patients. Lorenzo et al. reported that referral pattern was no significant association with causes of death in dialysis patients [15]. However, Herget-Rosenthal et al. showed that cardiovascular death was increased in LR versus ER (patient number, 4 versus 1) [26]. In this study, we showed the data that cardiovascular death was increased in LR versus ER, and the cardiovascular death free survival rate in ER was significantly better than that in LR. Blood pressure was well controlled in the early referral (ER) group. However, ER significantly lowered all-cause mortality and cardiovascular mortality after adjusting for systolic blood pressure in the multivariate analysis. Recently, Winkelmayer et al. reported that estimated annual reductions in 1-year mortality rates were 0.9% (95% CI, 0.7% - 1.1%) in ER (>90 days), and there was no material improvement in 1-year survival rates after dialysis initiation among 323,977 patients [5]. But, considering the duration of patients’ referrals to a nephrologist, the timing of early referral (>90 days) was a short period in which to evaluate and educate ESRD patients. In the present study, with increasing age, the risk for mortality due to late referral increased in the total patient population. In particular, in older patients there was a big difference in the hazard ratio between ER and LR (<1 year) patients.

It has been reported that patient education by nephrologists before initiation of dialysis decreases the likelihood of the need for urgent dialysis, resulting in a reduction in the need for the creation of a temporary vascular access [27]. Schmidt et al. showed that the need for emergency HD was significantly less among ER patients compared with LR patients (22% versus 90%) [13]. Our analysis also found that the likelihood of patients referred early receiving emergency HD using a temporary vascular catheter was significantly reduced. A previous study has shown that reduced use of a temporary vascular catheter is associated with decreased patient morbidity and mortality through reduced systemic infection rates [28].

Patients who were referred earlier are prepared for dialysis initiation, resulting in fewer emergent hospitalizations. Smart et al. showed a reduction of 8.8 days (95% CI, -10.7 to -7.0 days, P<0.00001) in those referred earlier to a nephrologist [29]. However, the hospitalization-free survival rate was no different for ER and LR patients in our study.

In this study, ER patients were well educated about dialysis by a nurse or nephrologist. Furthermore, BP, serum phosphate, total cholesterol, and LDL cholesterol were well controlled in the ER group. This could reduce the cardiovascular mortality rate and all-cause mortality in ER patients. Thus, timely referral to a nephrologist at least 1 year before dialysis initiation is important to reduce mortality even in older patients. Predialysis nephrology care is a much wider concept than providing the patient with dialysis access. It is important for the nephrologist to give patients information about CKD and offer personal education about dialysis or lifestyle modification. ER provides identification and correction of reversible causes of CKD, and preparation of dialysis. Timely referral is expected to influence long-term survival in ESRD patients.

Our results are informative, but this study has a limitation. This study had a relatively short follow-up period, with a maximum of 36 months. This was a short period in which to analyze the survival in ESRD patients.

In conclusion, timely referral to a nephrologist in the predialytic stage is associated with reduced mortality.

**Supporting Information**

**Table S1 Multivariate Cox proportional hazard models of independent factors of cardiovascular free survival. (DOC)**

**Author Contributions**

Conceived and designed the experiments: DHK JPL. Performed the experiments: YLK SWK CWY NHK YSK. Analyzed the data: MK HK. Wrote the paper: DHK YSK JPL.

---

**References**

1. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, et al. (2010) Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 55: S1–420, A426–427.

2. NHIC (2004) 2003 National Health Insurance Statistical Yearbook. Seoul, Korea. National Health Insurance Corporation (NHIC).

3. Jones C, Rosedick P, Harris S, Rogerson M (2006) Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 21: 2153–2159.

4. Stack AG (2002) Determinants of modality selection among incident US dialysis patients: results from a national study. J Am Soc Nephrol 13: 1279–1287.

5. Winkelmayer WC, Glynn RJ, Levin R, Owen W Jr, Avorn J (2001) Late referral and modality choice in end-stage renal disease. Kidney Int 60: 1547–1554.

6. Casas A, Cunningham J, Snellng P, Ayanian JZ (2003) Late referral to a nephrologist reduces access to renal transplantation. Am J Kidney Dis 42: 1043–1049.

7. Winkelmayer WC, Mehta J, Chandraker A, Owen WF Jr, Avorn J (2007) Predialysis nephrologist care and access to kidney transplantation in the United States. Am J Transplant 7: 872–879.

8. Stelham-Breen CO, Sherrard DJ, Gillen D, Capo M (2000) Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int 57: 639–645.

9. Astor BC, Eastace JA, Powel NR, Klag MJ, Sadler JH, et al. (2001) Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 38: 494–501.
10. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, et al. (2002) Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 55: 711–716.
11. Kazmi WH, Obrador GT, Khan SS, Pereira BJ, Kausz AT (2004) Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant 19: 1808–1814.
12. Dogan E, Erkoc R, Sayarluglu H, Durmus A, Topal C (2005) Effects of late referral to a nephrologist in patients with chronic renal failure. Nephrology (Carlton) 10: 516–519.
13. Schmidt RJ, Domino JR, Sorkin MI, Hobbs G (1998) Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 32: 278–283.
14. Curris BM, Barrett BJ, Jindal K, Djurdjev O, Levin A, et al. (2002) Canadian survey of clinical status at dialysis initiation 1998–1999: a multicenter prospective survey. Clin Nephrol 58: 282–288.
15. Lorenzo V, Martin M, Ruffino M, Hernandez D, Torres A, et al. (2004) Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients: an observational cohort study. Am J Kidney Dis 43: 999–1007.
16. Winkelmayer WC, Liu J, Chertow GM, Tamura MK (2011) Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med 171: 1371–1378.
17. Quaglia M, Canavesi C, Stratta P (2011) Early nephrology referral: how early is early enough? Arch Intern Med 171: 2065–2066, author reply 2067.
18. Di Napoli A, Valle S, d’Adamo G, Pezzotti P, Chica S, et al. (2010) Survey of determinants and effects of timing of referral to a nephrologist: the patient’s point of view. J Nephrol 23: 603–613.
19. Levy AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470.
20. (2012) Comprehensive Prospective Study of Clinical Research Center for End Stage Renal Disease (CRC ESRD). Available: http://webdb.crc-esrd.or.kr. Accessed July.
21. Charlton HE, Pompei P, Alex KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
22. Chae JW, Song CS, Kim H, Lee KB, Soo BS, et al. (2011) Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract 117: c379–384.
23. Davies SJ, Russell I, Bryan J, Phillips L, Russell GI (1995) Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 26: 353–361.
24. Roubiek C, Brunet P, Huiart L, Thirion X, Leonetti F, et al. (2000) Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis 36: 35–41.
25. de Jager DJ, Voormolen N, Krediet RT, Dekker FW, Boeschoten EW, et al. (2011) Association between time of referral and survival in the first year of dialysis in diabetes and the elderly. Nephrol Dial Transplant 26: 652–658.
26. Herget-Rosenbal S, Quellmann T, Linden G, Hollebeek M, Junkowski V, et al. (2010) How does late nephrological co-management impact chronic kidney disease? – an observational study. Int J Clin Pract 64: 1784–1792.
27. Inaguma D, Tatsumoto M, Shiino H, Suasuki S, Mishima T, et al. (2006) Effect of an educational program on the predialysis period for patients with chronic renal failure. Clin Exp Nephrol 10: 274–278.
28. Lemaire X, Morena M, Leray-Moragues H, Henriot-Viprey D, Chenini L, et al. (2009) Analysis of risk factors for catheter-related bacteremia in 2000 permanent dual catheters for hemodialysis. Blood Purif 26: 21–28.
29. Smart NA, Titus TT (2011) Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 124: 1073–1080 e1072.